Lymphoma and Myeloma 2009: An International Congress on Hematologic Malignancies

- , Waldorf=Astoria, New York, USA

Témata:

Biology of CLL

  • New insights into CLL biology
  • CLL genomics and epigenetics
  • How do we make sense of prognostic markers?

Treatment of CLL

  • Standard treatment of CLL: Evidencebased approaches to untreated and previously treated patients
  • Evidence-based approaches for relapsed treatment
  • Latest results with IMiDS compounds in CLL: How do we manage the rash/flare and what does it mean?
  • Experimental and recently approved novel agents in CLL

Lymphoplasmocytic disorders

  • Waldenstrom’s macroglobulinemia: An update
  • POEMS and Castleman’s disease: Is there a role for novel agents?
  • Amyloidosis: Recent data

Biology of lymphoma

  • The biologic and pathologic basis for the new WHO classification
  • A clinician’s view of the new

WHO classification

  • John Ultmann Award Lecture: Hodgkin’s disease: The past, the present and the future

T cell lymphoma

  • What is the best front line strategy for peripheral T-cell lymphoma: Is there a role of novel agents and transplantation?
  • Have we made progress in the systemic therapy of treating cutaneous T-cell lymphoma?
  • Angioimmunoblastic lymphadenopathy: What is latest in biology and treatment

Mantle cell lymphoma

  • Debate: Should mantle cell be treated aggressively from the onset?

Special concerns in large cell lymphoma

  • Biology and treatment of bulky and mediastinal large cell disease: Is EPOCH really better than CHOP-R with/without radiation?
  • How to prevent and treatment central nervous system disease
  • How can we improve on large cell lymphoma treatment?
  • Genomic/epigenetic targeting of large cell lymphoma: Does it have clinical application?

Low grade lymphoma

  • Is follicular lymphoma curable? If not, has it become a chronic illness?
  • Strategies for low grade lymphoma: How to use prognostic indicators in treatment
  • Lymphomas of the eye: MALT, follicular, large cell
  • Novel agents in low grade lymphoma: More than we can handle?
  • Vaccines redux: Useless or a phoenix?

Hodgkin’s disease: PET scanning

  • Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma
  • The new promise of PET scans
  • The new peril of PET scans

Biology of myeloma

  • Chromosomes, genomics and proteomics as a disease primer
  • Myeloma cell trafficking and mobilization
  • Debate: Does the myeloma stem cell exist? Can we target it for therapeutic purposes?
  • Targeting the cell cycle in myeloma and lymphoma

Clinical pathology and myeloma

  • Measurement of free light and heavy chains: Applications?
  • Minimal residual disease in myeloma: Flow cytometry and molecular techniques
  • The Tower of Babel: Multiple response criteria and the need for a unified standard: Summary of the IMW consensus on response criteria and relevant outcomes
  • Special lecture: Targeted therapy in myeloma
  • Joseph Michaeli Award Lecture: Kinetics, proliferation and novel agents in myeloma: Is autologous transplantaion old hat?

Clinical cases and debates in myeloma

  • First Line Therapy: Poor risk patient
  • Debate: Sequential vs. combination therapy, triplets or more
  • Consolidaton: Good risk patient

Debate: Transplant vs. no transplant

  • First Line Therapy: Non transplant candidate
  • Debate: Bortezomib based vs. IMiD based

Relapse and refractory disease

  • Novel combination therapies for the treatment of relapsed/refractory multiple myeloma: Current phase I/II, combinations using as backbone IMiDs and proteasome inhibitors

Special lecture

  • Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure in myeloma?

Aktivní účast

  • Odevzdávání abstrakt do 23. července 2009

Pasivní účast

Thursday October 22, 2009
8:00 am Welcome
Morton Coleman, MD

CLL Section

8:05 am Introduction
Richard R. Furman, MD

Session I: Biology of CLL
Moderator: John C. Byrd, MD

8:10 am New insights into CLL biology
Speaker invited

8:30 am CLL genomics and epigenetics: What’s on the horizon for clinicians?
John C. Byrd, MD

8:50 am How do we make sense of prognostic markers in CLL when treating patients?
Kanti Rai, MD

9:10 am Panel discussion questions

9:30 am Break

Session II: Treatment of CLL
Moderator: Richard Furman, MD

9:50 am Evidence-based approaches for treatment-naďve patients
Neil Kaye, MD

10:10 am Evidence-based approaches for treating relapsed/refractory patients
Claire Dearden, BSc, MD, FRCP, FPCPath

10:30 am Latest results with IMiDS compounds in CLL: How do we manage the rash and flare?
Asher Chanan-Khan, MD

10:50 am Experimental and recently approved novel agents in CLL
Richard R. Furman, MD

11:10 am Panel discussion

11:20 am Presentation of the best CLL abstract

11:30 am Luncheon Symposium

Session III: Lymphoplasmocytic disorders
Moderator: David J. Wolf, MD

1:30 pm Waldenstrom’s macroglobulinemia: An update
Eva Kimby, MD, PhD

1:50 pm POEMS and Castleman’s disease: Is there a role for novel agents?
Angela Dispenzieri, MD

2:10 pm Amyloidosis: Recent data
Raymond L. Comenzo, MD

2:30 pm Break

Lyphoma Section

2:50 pm Introduction
John P. Leonard, MD

Session IV: Biology of lymphoma
Moderator: Wayne Tam, MD, PhD

2:55 pm The biologic and pathologic basis for the new WHO classification
Randy D. Gascoyne, MD

3:15 pm A clinician’s view of the new WHO classification
Speaker invited

3:35 pm Panel discussion

3:45 pm Presentation of the best Lymphoma abstract

3:55 pm The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: John Ultmann Award for Contributions to Lymphoma Research Recipient: Volker Diehl, MD
Presenter: Speaker invited

4:05 pm Hodgkin’s disease: The past, the present and the future
Volker Diehl, MD

4:35 pm Questions and answers

4:45 pm Adjourn

Friday October 23, 2009
8:00 am Welcome
Morton Coleman, MD

8:05 am Introduction
John P. Leonard, MD

Session V: T cell lymphoma
Moderator: Rebecca Elstrom, MD

8:10 am What is the best front line strategy for peripheral T-cell lymphoma: Is there a role of novel agents and transplantation?
Steven Horwitz, MD

8:30 am Have we made progress in the systemic therapy of treating cutaneous T-cell lymphoma?
Steven Rosen, MD

8:50 am Angioimmunoblastic lymphadenopathy: What is latest in biology and treatment?
Rebecca Elstrom, MD

9:10 am Panel discussion and questions

9:20 am Break

Session VI: Mantle cell lymphoma
Moderator: John P. Leonard, MD

9:40 am Debate: Should mantle cell lymphoma be treated aggressively from the onset?
Pro: Brad Kahl, MD
Con: Peter Martin, MD
Moderator: John P. Leonard, MD

10:20 am Discussion and questions

Session VII: Special concerns in large cell lymphoma
Moderator: Thomas Habermann, MD

10:30 am What is the best treat for low stage aggressive lymphomas?
Thomas Habermann, MD

10:50 am How to prevent and treatment central nervous system disease
Steven Bernstein, MD

11:10 am How can we improve on large cell lymphoma treatment?
Bertrand Coiffier, MD

11:30 pm Genomic/epigenetic targeting of large cell lymphoma: Does it have clinical application?
Ari Melnick, MD

11:50 pm Discussion and questions

12:00 pm Luncheon Symposium

Session VIII: Low grade lymphoma
Moderator: Peter McLaughlin, MD

2:00 pm Is follicular lymphoma curable? If not, has it become a chronic illness?
Peter McLaughlin, MD

2:20 pm Strategies for low grade lymphoma: How to use prognostic indicators in treatment
John P. Leonard, MD

2:40 pm Lymphomas of the eye: MALT, follicular, large cell
Morton Coleman, MD

3:00 pm Novel agents in low grade lymphoma: More than we can handle?
Bruce D. Cheson, MD

3:20 pm Vaccines redux: Useless or a phoenix?
Stephen Schuster, MD

3:40 pm Break

Session IX: Hodgkin’s disease:PET scanning
Moderator: Morton Coleman, MD

4:00 pm Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma

The new promise of PET scans
Martin Hutchings, MD, PhD

The new peril of PET scans
Sandra J. Horning, MD
Moderator: Morton Coleman, MD

4:30 pm Discussion and questions

4:45 pm Adjourn

Saturday October 24, 2009
Myeloma Section

8:05 am Introduction
Ruben Niesvizky, MD

Session X: Biology of myeloma
Moderator: Scott Ely, MD, MPH

8:10 am Chromosomes, genomics and proteomics as a disease primer: Is M-SMART smart?
Rafael Fonseca, MD

8:30 am Myeloma cell trafficking and mobilization
Speaker invited

8:50 am Debate: Does the myeloma stem cell exist? Can we target it for therapeutic purposes?
Suzanne Lentzsch, MD, PhD
Carol Ann Huff, MD

9:20 am Targeting the cell cycle in myeloma and lymphoma
Selina Chen- Kiang, PhD

9:40 am Discussion and questions

Session XI: Clinical pathology and myeloma
Moderator: Tomer Mark, MD

9:50 am Measurement of free light and heavy chains: Applications?
Arthur R. Bradwell, MD

10:05 am Minimal residual disease in myeloma: Flow cytometry and molecular techniques: Is MRD clinically relevant?
Speaker invited

10:25 am The Tower of Babel: Multiple response criteria and the need for a unified standard. Summary of the IMW consensus on response criteria and relevant outcomes
S. Vincent Rajkumar, MD

10:45 am Break

11:05 am The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Recipient: Phillip R. Greipp, MD
Presenter: Rafael Fonseca, MD

11:15 am Sass Foundation/ Michaeli Award Lecture Kinetics, proliferation, and novel agents in myeloma: Is autologous transplantation an anachronism?
Philip R. Greipp, MD

11:45 pm Presentation of the best Myeloma abstract

11:55 pm Special lecture: Targeted therapy in myeloma
Keith Stewart, M.B.Ch.B

12:20 pm Questions

12:25 pm Luncheon Symposium

Session XII: Clinical cases and debates in myeloma
Moderator: Ruben Niesvizky, MD

2:15 pm FIRST LINE THERAPY: Clinical case of poor risk patient
Debate: Sequential therapy vs.combination therapy, triplets or more
Jean-Luc Harousseau, MD (sequential)
Sagar Lonial, MD (combination)

2:45 pm CONSOLIDATION: Clinical case of good risk patient

Debate: Transplant vs. no transplant
Speaker invited (transplant)
Joan Bladée, MD (no transplant)

3:15 pm FIRST LINE THERAPY: Clinical case of non-transplant candidate
Debate: bortezomib based vs. IMiD based
Ruben Niesvizky, MD (bortezomib-based)
Antonio Palumbo, MD (IMiD-based)

Session XIII: Relapse/refractory disease
Moderator: Roger Pearse, MD

3:45 pm SECOND LINE THERAPY: Novel combination therapies for the treatment of relapsed/ refractory multiple myeloma: Current phase I/II combinations using IMiD compounds and proteasome inhibitors as the backbone
James R. Berenson, MD

4:05 pm Questions

Session XIV: Special lecture
Moderator: Morton Coleman, MD, FACP

4:10 pm Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure in myeloma?
Sundar Jagganath, MD

4:40 pm Questions

4:50 pm Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex.c...cements/a115-01.asp

  • Přidat do kalendáře: 2009-10-22 00:00:00 2009-10-24 23:59:59 Europe/Prague Lymphoma and Myeloma 2009: An International Congress on Hematologic Malignancies Témata: Biology of CLL New insights into CLL biology CLL genomics and epigenetics How do we make sense of prognostic markers? Treatment of CLL Standard treatment of CLL: Evidencebased approaches to untreated and previously treated patients Evidence-based approaches for relapsed treatment Latest results with IMiDS compounds in CLL: How do we manage the rash/flare and what does it mean? Experimental and recently approved novel agents in CLL Lymphoplasmocytic disorders Waldenstrom’s macroglobulinemia: An update POEMS and Castleman’s disease: Is there a role for novel agents? Amyloidosis: Recent data Biology of lymphoma The biologic and pathologic basis for the new WHO classification A clinician’s view of the new WHO classification John Ultmann Award Lecture: Hodgkin’s disease: The past, the present and the future T cell lymphoma What is the best front line strategy for peripheral T-cell lymphoma: Is there a role of novel agents and transplantation? Have we made progress in the systemic therapy of treating cutaneous T-cell lymphoma? Angioimmunoblastic lymphadenopathy: What is latest in biology and treatment Mantle cell lymphoma Debate: Should mantle cell be treated aggressively from the onset? Special concerns in large cell lymphoma Biology and treatment of bulky and mediastinal large cell disease: Is EPOCH really better than CHOP-R with/without radiation? How to prevent and treatment central nervous system disease How can we improve on large cell lymphoma treatment? Genomic/epigenetic targeting of large cell lymphoma: Does it have clinical application? Low grade lymphoma Is follicular lymphoma curable? If not, has it become a chronic illness? Strategies for low grade lymphoma: How to use prognostic indicators in treatment Lymphomas of the eye: MALT, follicular, large cell Novel agents in low grade lymphoma: More than we can handle? Vaccines redux: Useless or a phoenix? Hodgkin’s disease: PET scanning Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma The new promise of PET scans The new peril of PET scans Biology of myeloma Chromosomes, genomics and proteomics as a disease primer Myeloma cell trafficking and mobilization Debate: Does the myeloma stem cell exist? Can we target it for therapeutic purposes? Targeting the cell cycle in myeloma and lymphoma Clinical pathology and myeloma Measurement of free light and heavy chains: Applications? Minimal residual disease in myeloma: Flow cytometry and molecular techniques The Tower of Babel: Multiple response criteria and the need for a unified standard: Summary of the IMW consensus on response criteria and relevant outcomes Special lecture: Targeted therapy in myeloma Joseph Michaeli Award Lecture: Kinetics, proliferation and novel agents in myeloma: Is autologous transplantaion old hat? Clinical cases and debates in myeloma First Line Therapy: Poor risk patient Debate: Sequential vs. combination therapy, triplets or more Consolidaton: Good risk patient Debate: Transplant vs. no transplant First Line Therapy: Non transplant candidate Debate: Bortezomib based vs. IMiD based Relapse and refractory disease Novel combination therapies for the treatment of relapsed/refractory multiple myeloma: Current phase I/II, combinations using as backbone IMiDs and proteasome inhibitors Special lecture Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure in myeloma? Waldorf=Astoria, New York, USA